Healionics’ Stargraft Arteriovenous Graft Evaluated in 24-Month Data

November 25, 2025—Healionics Corporation, a developer of synthetic biomaterial-based medical devices, announced recently that 24-month clinical results for its investigational Stargraft arteriovenous (AV) graft were presented by John Ross, MD, at the CiDA, the Controversies in Dialysis Access symposium.

This presentation and others on the Stargraft device are available on the company’s website at www.healionics.com/publications. Clinical evidence of Stargraft’s mechanism of action was also presented at CiDA, noted the company.

According to Healionics, Stargraft AV device showed promise in addressing both issues of occlusion and infection as well as reducing the need for interventions to maintain graft function. The device maintained 100% primary unassisted patency (PUP) through 12 months postimplantation with no interventions required to maintain sufficient blood flow for dialysis therapy. Through 24 months, it maintained 80% PUP and a 0% infection rate.

The company noted that these results compared favorably with the outcomes of on-market AV grafts that demonstrated a PUP of 41% at 12 months and 28% at 24 months, and infection rates of 9% per year in a study by Robert J. Halbert, MD, et al published in Kidney360 (2020;1:1437-1446).

Stargraft is not yet available for commercial sale, advised Healionics.